CR10788A - Nuevos anticuerpos antiproliferativos - Google Patents
Nuevos anticuerpos antiproliferativosInfo
- Publication number
- CR10788A CR10788A CR10788A CR10788A CR10788A CR 10788 A CR10788 A CR 10788A CR 10788 A CR10788 A CR 10788A CR 10788 A CR10788 A CR 10788A CR 10788 A CR10788 A CR 10788A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antiproliferative antibodies
- antibodies
- new antiproliferative
- new
- functional
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0610329A FR2909092B1 (fr) | 2006-11-24 | 2006-11-24 | Nouveaux anticorps anti-proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10788A true CR10788A (es) | 2009-06-23 |
Family
ID=37903981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10788A CR10788A (es) | 2006-11-24 | 2009-05-08 | Nuevos anticuerpos antiproliferativos |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8071730B2 (enExample) |
| EP (1) | EP2074148A1 (enExample) |
| JP (1) | JP2010509931A (enExample) |
| KR (1) | KR20090088878A (enExample) |
| CN (1) | CN101535344B (enExample) |
| AU (1) | AU2007324509B2 (enExample) |
| BR (1) | BRPI0719323A2 (enExample) |
| CA (1) | CA2670039A1 (enExample) |
| CL (1) | CL2007003357A1 (enExample) |
| CR (1) | CR10788A (enExample) |
| CU (1) | CU23792A3 (enExample) |
| EC (1) | ECSP099341A (enExample) |
| FR (1) | FR2909092B1 (enExample) |
| GE (1) | GEP20125629B (enExample) |
| GT (1) | GT200900126A (enExample) |
| IL (1) | IL198744A0 (enExample) |
| MA (1) | MA30891B1 (enExample) |
| MX (1) | MX2009005293A (enExample) |
| NI (1) | NI200900079A (enExample) |
| NO (1) | NO20092360L (enExample) |
| NZ (1) | NZ576174A (enExample) |
| RU (1) | RU2451689C2 (enExample) |
| SA (1) | SA07280637B1 (enExample) |
| TN (1) | TN2009000194A1 (enExample) |
| TW (1) | TW200829602A (enExample) |
| UA (1) | UA99602C2 (enExample) |
| WO (1) | WO2008062063A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| EP2313435A4 (en) | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
| WO2011053759A1 (en) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax1 and ax189 pcsk9 antagonists and variants |
| EA201390472A1 (ru) * | 2010-10-29 | 2014-02-28 | Иммьюноджен, Инк. | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты |
| EP2455403A1 (en) | 2010-11-23 | 2012-05-23 | Pierre Fabre Medicament | Homogeneous humanized antibodies against JAM-A that inhibit proliferation |
| US20130287790A1 (en) * | 2012-03-30 | 2013-10-31 | The Board Of Trustees Of The Leland Standford Junior University | Use of jam-a in diagnosing and treating leukemia |
| CN109369808B (zh) | 2012-08-24 | 2023-11-07 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
| KR20150097304A (ko) | 2014-02-18 | 2015-08-26 | 삼성전자주식회사 | 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체 |
| IL261200B2 (en) * | 2016-03-01 | 2023-03-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Antibodies specific for the human poliovirus receptor |
| WO2018005519A2 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| WO2018027039A1 (en) | 2016-08-03 | 2018-02-08 | Nextcure, Inc. | Compositions and methods for modulating lair signal transduction |
| CN109022366A (zh) * | 2018-08-16 | 2018-12-18 | 江南大学 | 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用 |
| CN114740108B (zh) * | 2022-03-28 | 2023-07-14 | 天津键凯科技有限公司 | 一种聚合物修饰抗体类药物的修饰度的测定方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9604470D0 (sv) * | 1996-12-04 | 1996-12-04 | Tamas Bartfai Konsulting Ab | Transmembrane component of tight junction |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20030171568A1 (en) * | 1998-09-16 | 2003-09-11 | Avi Ashkenazi | Use of A33 antigens and JAM-IT |
| PT1069185E (pt) * | 1998-04-03 | 2011-08-11 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra factor tecidual (tf) humano e processo para construção de um anticorpo humanizado |
| EP2292761A1 (en) * | 1999-03-11 | 2011-03-09 | Merck Serono S.A. | Vascular adhesion molecules and modulation of their function |
| WO2005060457A2 (en) * | 2003-12-04 | 2005-07-07 | Pdl Biopharma, Inc. | Treatment of inflammatory bowel diseases with anti-ip-10 antibodies |
| WO2006008076A2 (en) * | 2004-07-16 | 2006-01-26 | Universita Degli Studi Di Milano | Methods and agents stimulating the immune response |
| WO2006121207A1 (en) * | 2005-05-12 | 2006-11-16 | Oncotherapy Science, Inc. | Methods for damaging cells using effector function of anti-dsc2 antibody |
| WO2007127476A2 (en) * | 2006-04-28 | 2007-11-08 | Oregon Health & Science University | Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cell |
-
2006
- 2006-11-24 FR FR0610329A patent/FR2909092B1/fr not_active Expired - Fee Related
-
2007
- 2007-11-23 AU AU2007324509A patent/AU2007324509B2/en not_active Ceased
- 2007-11-23 CL CL200703357A patent/CL2007003357A1/es unknown
- 2007-11-23 RU RU2009123409/10A patent/RU2451689C2/ru not_active IP Right Cessation
- 2007-11-23 MX MX2009005293A patent/MX2009005293A/es active IP Right Grant
- 2007-11-23 KR KR1020097009675A patent/KR20090088878A/ko not_active Ceased
- 2007-11-23 CN CN2007800405398A patent/CN101535344B/zh not_active Expired - Fee Related
- 2007-11-23 JP JP2009537651A patent/JP2010509931A/ja not_active Ceased
- 2007-11-23 BR BRPI0719323-8A patent/BRPI0719323A2/pt not_active IP Right Cessation
- 2007-11-23 WO PCT/EP2007/062760 patent/WO2008062063A1/en not_active Ceased
- 2007-11-23 UA UAA200906473A patent/UA99602C2/ru unknown
- 2007-11-23 GE GEAP200711322A patent/GEP20125629B/en unknown
- 2007-11-23 NZ NZ576174A patent/NZ576174A/en not_active IP Right Cessation
- 2007-11-23 EP EP07847306A patent/EP2074148A1/en not_active Withdrawn
- 2007-11-23 CA CA002670039A patent/CA2670039A1/en not_active Abandoned
- 2007-11-24 SA SA07280637A patent/SA07280637B1/ar unknown
- 2007-11-26 TW TW096144763A patent/TW200829602A/zh unknown
-
2008
- 2008-05-22 US US12/125,726 patent/US8071730B2/en not_active Expired - Fee Related
-
2009
- 2009-05-06 NI NI200900079A patent/NI200900079A/es unknown
- 2009-05-08 CR CR10788A patent/CR10788A/es unknown
- 2009-05-14 IL IL198744A patent/IL198744A0/en unknown
- 2009-05-14 CU CU20090082A patent/CU23792A3/es not_active IP Right Cessation
- 2009-05-14 GT GT200900126A patent/GT200900126A/es unknown
- 2009-05-14 MA MA31875A patent/MA30891B1/fr unknown
- 2009-05-18 TN TNP2009000194A patent/TN2009000194A1/fr unknown
- 2009-05-18 EC EC2009009341A patent/ECSP099341A/es unknown
- 2009-06-19 NO NO20092360A patent/NO20092360L/no not_active Application Discontinuation
-
2011
- 2011-12-05 US US13/310,840 patent/US20120156191A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100092455A1 (en) | 2010-04-15 |
| EP2074148A1 (en) | 2009-07-01 |
| MX2009005293A (es) | 2009-08-07 |
| TN2009000194A1 (en) | 2010-10-18 |
| FR2909092A1 (fr) | 2008-05-30 |
| SA07280637B1 (ar) | 2012-04-11 |
| AU2007324509A1 (en) | 2008-05-29 |
| NO20092360L (no) | 2009-08-11 |
| MA30891B1 (fr) | 2009-11-02 |
| GT200900126A (es) | 2011-09-02 |
| WO2008062063A1 (en) | 2008-05-29 |
| UA99602C2 (ru) | 2012-09-10 |
| TW200829602A (en) | 2008-07-16 |
| AU2007324509B2 (en) | 2013-01-17 |
| NZ576174A (en) | 2012-03-30 |
| RU2009123409A (ru) | 2010-12-27 |
| RU2451689C2 (ru) | 2012-05-27 |
| KR20090088878A (ko) | 2009-08-20 |
| IL198744A0 (en) | 2010-02-17 |
| CA2670039A1 (en) | 2008-05-29 |
| US20120156191A1 (en) | 2012-06-21 |
| CN101535344A (zh) | 2009-09-16 |
| CN101535344B (zh) | 2013-10-16 |
| BRPI0719323A2 (pt) | 2014-02-04 |
| CU23792A3 (es) | 2012-03-15 |
| NI200900079A (es) | 2010-11-10 |
| ECSP099341A (es) | 2009-06-30 |
| US8071730B2 (en) | 2011-12-06 |
| JP2010509931A (ja) | 2010-04-02 |
| HK1132752A1 (en) | 2010-03-05 |
| FR2909092B1 (fr) | 2012-10-19 |
| CL2007003357A1 (es) | 2008-04-04 |
| GEP20125629B (en) | 2012-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10788A (es) | Nuevos anticuerpos antiproliferativos | |
| MX2007014132A (es) | Compuestos de diarilhidantoina. | |
| CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
| DK1874821T3 (da) | Kombination af antistoffer med glykokortikoider til behandling af kræft | |
| CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
| CY2013046I2 (el) | Καινοτομος χρηση των αντισωματων αντι il-1bhta | |
| CR9947A (es) | Compuestos de pirimidinil benzotiofeno | |
| CL2008003940A1 (es) | Compuestos derivados de morfolino pirimidina sustituida; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de cancer, enfermedades inflamatorias, enfermedades obstructivas de las vias aereas, enfermedades inmunes o enfermedades cardiovasculares. | |
| HRP20180579T1 (hr) | Postupak za priređivanje glikoziliranog interferona beta | |
| ECSP088122A (es) | Composiciones y métodos para el diagnóstico y el tratamiento de tumores | |
| ATE512663T1 (de) | Kombination zur behandlung von erkrankungen mit zellproliferation | |
| PT1928223E (pt) | Singularizador de sementes | |
| MY142988A (en) | Novel aminobenzophenone compounds | |
| CL2012000768A1 (es) | Compuestos derivados de acido l-glutamico y l-glutamina marcados con [18f]; procedimiento de preparacion; y su uso para el diagnostico de enfermedades tumorales. | |
| CR9872A (es) | Diazepinoquinolinas, su sintesis e intermediarios | |
| DE602005016127D1 (de) | Substituierte hydantoine zur krebsbehandlung | |
| WO2007061939A3 (en) | Metabolite derivatives of the hdac inhibitor fk228 | |
| FI8398U1 (fi) | Rakenne- tai koristekappale | |
| ECSP088151A (es) | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas | |
| CA113787S (en) | Lever | |
| GT200500130A (es) | Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| EP1863520A4 (en) | USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER | |
| EP1959978A4 (en) | COMPOSITIONS OF ALPHA-FETOPROTEIN AND APOPTOSIS INDUCTORS FOR THE TREATMENT OF CANCER | |
| EA200701592A1 (ru) | Композиты и способы их получения и использования | |
| DOP2006000087A (es) | Compuestos heteroaromaticos acilaminobiciclicos y sus usos |